Cancer drug trial halted midway: what happened?

NCT ID NCT04504916

Terminated Disease control Sponsor: VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested an experimental drug called VLS-101 in 102 people with advanced solid tumors, including breast, lung, ovarian, stomach, and pancreatic cancers that had stopped responding to standard treatments. The goal was to see if the drug could shrink tumors. However, the trial was terminated early, so results are limited.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ER POSITIVE BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

estrogen-receptor negative breast cancer estrogen-receptor positive breast cancer gastric cancer gastric neoplasm Her2-receptor negative breast cancer malignant pancreatic neoplasm non-small cell lung carcinoma ovarian carcinoma pancreatic neoplasm progesterone-receptor negative breast cancer progesterone-receptor positive breast cancer triple-negative breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ER POSITIVE BREAST CANCER ER-NEGATIVE BREAST CANCER ESTROGEN RECEPTOR- NEGATIVE BREAST CANCER ESTROGEN-RECEPTOR-POSITIVE BREAST CANCER GASTRIC CANCER HER2-NEGATIVE BREAST CANCER NON-SQUAMOUS NON-SMALL CELL LUNG CANCER NSCLC PANCREATIC CANCER PLATINUM-RESISTANT OVARIAN CANCER PR-NEGATIVE BREAST CANCER PR-POSITIVE BREAST CANCER PROGESTERONE-RECEPTOR NEGATIVE BREAST CANCER PROGESTERONE-RECEPTOR-POSITIVE BREAST CANCER TRIPLE NEGATIVE BREAST CANCER

Contacts and locations

Locations

AdventHealth Orlando ( Site 0003)

Orlando, Florida, 32804, United States
BC Cancer Vancouver ( Site 0011)

Vancouver, British Columbia, V5Z 4E6, Canada
Centre intégré de cancérologie du CHU de Québec Université Laval, Hôpital de l'Enfant-Jésus ( Site 0

Québec, Quebec, G1J 1Z4, Canada
Centre intégré de cancérologie du CHUM ( Site 0016)

Montreal, Quebec, H2X 0A9, Canada
Cross Cancer Institute ( Site 0012)

Edmonton, Alberta, T6G 1Z2, Canada
Jewish General Hospital ( Site 0013)

Montreal, Quebec, H3T 1E2, Canada
John Theurer Cancer Center at Hackensack University Med Ctr ( Site 0002)

Hackensack, New Jersey, 07601, United States
MD Anderson ( Site 0001)

Houston, Texas, 77030, United States
Massachusetts General Hospital ( Site 0017)

Boston, Massachusetts, 02114, United States
Memorial Regional Hospital-Memorial Cancer Institute ( Site 0005)

Hollywood, Florida, 33021, United States
Memorial Sloan Kettering Cancer Center ( Site 0007)

New York, New York, 10021, United States
Princess Margaret Cancer Centre ( Site 0006)

Toronto, Ontario, M5G 2M9, Canada
Swedish Medical Center ( Site 0008)

Seattle, Washington, 98104, United States
The University of Texas Health Science Center at San Antonio ( Site 0004)

San Antonio, Texas, 78229, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.